Comparative efficacy and safety of multitarget angiogenesis inhibitor combined with immune checkpoint inhibitor and nivolumab monotherapy as second-line or beyond for advanced lung adenocarcinoma in driver-negative patients: a retrospective comparative cohort study

BACKGROUND: The efficacy of immune monotherapy is not satisfactory in patients with advanced, treated non-small cell lung cancer (NSCLC). Combining antiangiogenic agents and immune checkpoint inhibitors (ICIs) can counteract the immunosuppression and confer synergistic therapeutic benefits. We explo...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Lian, Xu, Jianlin, Qiao, Rong, Zhong, Hua, Brueckl, Wolfgang M., Zhong, Runbo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10261869/
https://www.ncbi.nlm.nih.gov/pubmed/37323173
http://dx.doi.org/10.21037/tlcr-23-260

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10261869/
https://www.ncbi.nlm.nih.gov/pubmed/37323173
http://dx.doi.org/10.21037/tlcr-23-260

Ejemplares similares